Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVEDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. JUVEDERM VOLUMA XC is the first and only hyaluronic acid dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
- Regenxbio expects cash to fund operations into 2H25
- AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
- Genmab, AbbVie announce FDA priority review for sBLA
- Truist biotech analysts hold an analyst/industry conference call
